Engineered Bacteria for Metabolic Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metabolic diseases such as obesity and type 2 diabetes are inadequate, as they often come with systemic side effects and are not long-term solutions, and there is a need for therapies that can effectively target multiple metabolic organs without adverse effects.
Innovation Solution
Genetically engineered bacteria are developed to produce metabolic and satiety effector molecules, as well as modulators of inflammation and excess bile salt levels, specifically designed to operate in low-oxygen environments like the gut, which are non-pathogenic and stably maintained in vivo, producing therapeutic molecules like propionate, butyrate, and GLP-1 analogs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (insulin, thiazolidinedione, DPP-4 inhibitors) are used to treat metabolic diseases, then metabolic control is improved, but systemic side effects and life-threatening adverse events occur
Solution Approach 1:
The patent applies local quality by engineering bacteria to produce therapeutic molecules specifically in the gut environment rather than systemic administration. The bacteria are designed to sense gut-specific conditions (low oxygen, presence of bile salts) and produce effector molecules locally, thereby achieving metabolic control while avoiding systemic side effects associated with conventional treatments like insulin and thiazolidinedione.
Solution Approach 2:
The patent uses genetically engineered bacteria as intermediaries to deliver therapeutic molecules. These bacteria act as living carriers that sense gut conditions and produce effector molecules (such as GLP-1 analogs, bile salt hydrolases) in response to specific triggers, thereby mediating the therapeutic effect locally in the gut without requiring systemic administration of drugs that cause adverse events.
2Reliability
If multiple therapies are developed to treat type 2 diabetes, then metabolic regulation is improved, but life-threatening side effects occur
Solution Approach 1:
The patent implements local quality by confining therapeutic molecule production to the gut environment through engineered bacterial sensors that detect gut-specific conditions (low oxygen tension, presence of bile salts). This localized production approach achieves metabolic regulation while eliminating the life-threatening side effects associated with systemic therapies.
Solution Approach 2:
The patent applies parameter changes by designing bacteria to respond to specific environmental parameters (oxygen levels, bile salt concentration) and produce therapeutic molecules only when these parameters indicate gut conditions. This conditional expression strategy enables metabolic regulation while avoiding adverse effects by controlling where and when therapy is activated.
3Reliability
If insulin is administered multiple times throughout the day to treat severe type 2 diabetes, then blood glucose control is improved, but quality of life deteriorates
Solution Approach 1:
The patent applies self-service by engineering bacteria to autonomously sense gut conditions and produce therapeutic molecules without requiring external administration. The bacteria function as self-regulating therapeutic systems that respond automatically to gut environmental cues, eliminating the need for multiple daily injections and thereby improving quality of life while maintaining blood glucose control.
Solution Approach 2:
The patent implements preliminary action by administering the engineered bacteria orally once, which then colonize the gut and continuously provide therapeutic function. This single preliminary administration establishes a self-sustaining therapeutic system that eliminates the need for repeated dosing, thereby improving quality of life while maintaining effective blood glucose control.
4Reliability
If strict diet and exercise regimes are enforced to treat obesity, then energy balance is improved, but adherence becomes challenging
Solution Approach 1:
The patent applies self-service by using engineered bacteria that autonomously sense gut conditions and produce therapeutic molecules to promote energy balance. This eliminates the need for patients to manually enforce diet and exercise regimes, as the bacteria self-regulate therapeutic molecule production based on gut environmental cues, thereby improving adherence while maintaining energy balance control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These bacteria provide a stable and effective treatment for metabolic diseases by producing therapeutic molecules that target metabolic disorders, reducing excess bile salts and modulating inflammation, thereby addressing the limitations of existing treatments and offering a long-term solution.
Implementation Method 1
bacteria that are genetically engineered to treat, modulate, and/or ameliorate metabolic diseases, particularly in low-oxygen environments, such as in the mammalian gut
Data Source
AI summary
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of attenuating metabolic diseases are disclosed.